CatalystAlertBeta

Briefing Calendar News IPOs Catalyst Radar Research Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

CatalystAlert is a biotech catalyst intelligence platform tracking FDA decisions, PDUFA dates, and clinical-trial readouts for 1,600+ biotech stocks. Every catalyst date carries a confidence rating — confirmed against an official regulatory source, estimated, or AI-detected — alongside AI entry-timing and a public, scored prediction track record.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary
Best Catalyst Tools
What's New

Compare

vs BioPharmCatalyst
vs BioMarkets.io
vs Biocat
vs BioCatalyst
vs ClinicalInvestor

Legal

About
CeliA (AI assistant)
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

Legal & disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All signals, probability scores, and analyses are based on historical data and machine-learning models. Past performance does not guarantee future results, and biotech is a volatile sector where outcomes are uncertain.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar Watchlist News Learn Account

Tarlatamab - Phase 3 | AMGN Pipeline | CatalystAlert

Tarlatamab

Phase 3

Amgen Inc. (AMGN)

00%

Orphan DrugFast TrackBreakthrough TherapyLearn about designations

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

AMGNPhase 2$182.2B

Tarlatamab Phase 2 Est. Readout

Tarlatamab• Small Cell Lung Cancer222

BTDFTOrphan

Q4 2026~QConfirmed

00%

Competitive Landscape

4 competitors in Small Cell Lung Cancer

GTHXCarboplatin

View Full Landscape

Drug Information

Target Indication

Small Cell Lung Cancer

Mechanism of Action

BiTE (DLL3xCD3)

Clinical Trial

Last updated: 12/3/2025

Patent & Exclusivity

No Patent Data

Application

Source: FDA Orange Book

Regulatory Approvals

EMA5/29/2026

Imdylltra

Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.

Orphan

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

AMG 162 / DenosumabPhase 3

Breast Cancer

Etanercept LiquidPhase 3

Rheumatoid Arthritis

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Darbepoetin alfa - 2.25 mcg/kgPhase 3

Anemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.